Evidence mapPaperPMID 35565731Full record

Trial reportNutrients2022

A Randomised, Double-Blind, Placebo-Controlled Crossover Trial of Resveratrol Supplementation for Prophylaxis of Hormonal Migraine.

Jemima S A Dzator, Peter R C Howe, Kirsten G Coupland, Rachel H X Wong

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Resveratrol and Gut Microbiota Synergy: Preventive and Therapeutic Effects.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Jemima S A DzatorSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.
Peter R C HoweSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.ORCID 0000-0001-6546-7742
Kirsten G CouplandSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.
Rachel H X WongSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan 2308, Australia.
University of Southern Queensland · AUHunter Medical Research Institute · AUUniversity of Newcastle Australia · AU

Funding

Evolva (Switzerland) 2000006
6 · The paper itself

Abstract

Resveratrol, a vasoactive phytoestrogen, has beneficial effects on cerebrovascular function. Previous research has shown that hormonal migraineurs have poorer cerebrovascular function than non-migraineur women. We aimed to investigate if resveratrol supplementation for three months could reduce the hormonal migraine burden index (HMBI: the number of days with menstrual migraine per month), reduce migraine-related disability and improve migraine-related quality of life. A randomised, double-blind, placebo-controlled, crossover, intervention trial was conducted in 62 hormonal migraineurs (mean age: 37.5 ± 0.8 years). Participants consumed 75 mg of resveratrol or matching placebo capsules twice daily for three months before crossing over to the other treatment arm. Participants completed a daily diary and the Headache Impact Test-6™, Migraine Disability Assessment and Migraine-Specific Quality of Life questionnaires at months 0, 3 and 6. The HMBI was the primary outcome and was calculated using data extracted from the participant's diary. No differences in the HMBI (

Indexed as

Migraine DisordersQuality of LifeAdultCross-Over StudiesDietary SupplementsDouble-Blind MethodFemaleHeadacheHumansResveratrolTreatment OutcomeResveratrolcerebrovascular functionhormonal migrainemigraine disability assessmentnutrient interventionphytoestrogenprophylaxisresveratrol

Identifiers

PMID35565731
PMCPMC9100551
OpenAlexW4224325992

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.